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Background
Chronic migraine (CM) affects 2% of the population and
Botox is the only licensed treatment for prevention of
adult patients with CM.
In the UK, National Institute for Clinical Excellence
(NICE) approved its use on the National Health Service
(NHS) provided patients had failed three preventive
medications and appropriately addressed for medication
overuse.
NICE defines responder with 30% reduction in head-
ache days without emphasis on severity of headache or
number of migraine days.
We developed Hull Criteria that defines responder as
one with either:
50% reduction in either
Headache days
Or migraine days
An increment in crystal clear days twice that of
baseline
Objectives
To compare the outcomes of patients receiving Botox
treatment in CM according to NICE and Hull Criteria.
Method
Adult patients with CM attending the Hull migraine
clinic were offered Botox based on clinical needs and
maintained a headache diary.
Data were extracted for headache, migraine, and head-
ache-free days
Responder rate was assessed applying Hull and NICE
criteria.
Results
Out of a cohort of 357 patients having received a total of
858 cycles, we analysed 151 patients who had received
two treatment cycles as recommended by NICE.
A Significant number of patients who responded with
Hull Criteria did not satisfy NICE criteria and were
denied treatment.
Discussion
We recommend that severity of headache and number
of migraine days must be taken in to account in evaluat-
ing response rate to Botox.
NICE criteria should include reduction in migraine
days in addition to headache days.
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